Lexicon Pharmaceuticals Inc (NASDAQ:LXRX)

1.62
Delayed Data
As of May 25
 -0.01 / -0.62%
Today’s Change
1.56
Today|||52-Week Range
6.33
-58.88%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$265.5M

Company Description

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Contact Information

Lexicon Pharmaceuticals, Inc.
2445 Technology Forest Boulevard
The Woodlands Texas 77381-1160
P:(281) 863-3000
Investor Relations:
(281) 863-3421

Employees

Shareholders

Mutual fund holders9.86%
Other institutional69.09%
Individual stakeholders51.95%

Top Executives

Lonnel CoatsChief Executive Officer & Director
Jeffrey L. WadePresident & Chief Financial Officer
Craig B. GranowitzChief Medical Officer & Senior Vice President
Brian T. CrumSecretary, Senior Vice President & General Counsel
Kiernan A. SethChief Commercial Officer & Vice President